Aytu BioPharma (AYTU) Revenue & Revenue Breakdown
Aytu BioPharma Revenue Highlights
Latest Revenue (Y)
$107.40M
Latest Revenue (Q)
$17.99M
Main Segment (Y)
Consumer Health Portfolio
Main Geography (Y)
UNITED STATES
Aytu BioPharma Revenue by Period
Aytu BioPharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-06-30 | $107.40M | 11.10% |
| 2022-06-30 | $96.67M | 47.29% |
| 2021-06-30 | $65.63M | 137.52% |
| 2020-06-30 | $27.63M | 277.47% |
| 2019-06-30 | $7.32M | 100.01% |
| 2018-06-30 | $3.66M | 13.61% |
| 2017-06-30 | $3.22M | 25.72% |
| 2016-06-30 | $2.56M | 878.85% |
| 2015-06-30 | $261.78K | 344.23% |
| 2014-06-30 | $58.93K | 3267.37% |
| 2012-08-31 | $1.75K | 100.00% |
| 2011-08-31 | - | 100.00% |
| 2010-08-31 | - | -100.00% |
| 2009-08-31 | $1.75K | 100.00% |
| 2008-08-31 | - | 100.00% |
| 2007-08-31 | - | - |
Aytu BioPharma generated $107.40M in revenue during NA 2023, up 11.10% compared to the previous quarter, and up 2934.40% compared to the same period a year ago.
Aytu BioPharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $17.99M | -21.54% |
| 2023-12-31 | $22.93M | 3.78% |
| 2023-09-30 | $22.10M | -28.09% |
| 2023-06-30 | $30.73M | 35.19% |
| 2023-03-31 | $22.73M | -13.49% |
| 2022-12-31 | $26.28M | -4.98% |
| 2022-09-30 | $27.66M | 0.75% |
| 2022-06-30 | $27.45M | 13.43% |
| 2022-03-31 | $24.20M | 4.64% |
| 2021-12-31 | $23.13M | 5.61% |
| 2021-09-30 | $21.90M | -6.75% |
| 2021-06-30 | $23.48M | 74.17% |
| 2021-03-31 | $13.48M | -10.99% |
| 2020-12-31 | $15.15M | 12.03% |
| 2020-09-30 | $13.52M | -9.02% |
| 2020-06-30 | $14.86M | 82.20% |
| 2020-03-31 | $8.16M | 156.87% |
| 2019-12-31 | $3.18M | 120.53% |
| 2019-09-30 | $1.44M | -16.07% |
| 2019-06-30 | $1.72M | -27.85% |
| 2019-03-31 | $2.38M | 32.47% |
| 2018-12-31 | $1.80M | 25.35% |
| 2018-09-30 | $1.43M | 54.81% |
| 2018-06-30 | $925.00K | 52.39% |
| 2018-03-31 | $607.00K | -42.25% |
| 2017-12-31 | $1.05M | -2.32% |
| 2017-09-30 | $1.08M | 28.73% |
| 2017-06-30 | $835.89K | -6.50% |
| 2017-03-31 | $894.00K | 12.59% |
| 2016-12-31 | $794.00K | 13.75% |
| 2016-09-30 | $698.00K | -25.53% |
| 2016-06-30 | $937.30K | 40.23% |
| 2016-03-31 | $668.43K | 42.39% |
| 2015-12-31 | $469.43K | -3.68% |
| 2015-09-30 | $487.38K | 167.74% |
| 2015-06-30 | $182.04K | 663.93% |
| 2015-03-31 | $23.83K | - |
| 2015-02-28 | $23.83K | 100.00% |
| 2014-08-31 | - | -100.00% |
| 2014-05-31 | $1.00K | 100.00% |
| 2014-02-28 | - | 100.00% |
| 2013-08-31 | - | -100.00% |
| 2013-05-31 | $1.75K | 100.00% |
| 2013-02-28 | - | -100.00% |
| 2012-08-31 | $1.75K | 100.00% |
| 2012-05-31 | - | 100.00% |
| 2012-02-29 | - | 100.00% |
| 2011-08-31 | - | 100.00% |
| 2011-05-31 | - | 100.00% |
| 2011-02-28 | - | 100.00% |
| 2010-08-31 | - | 100.00% |
| 2010-05-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-08-31 | - | -100.00% |
| 2009-05-31 | $1.75K | 100.00% |
| 2009-02-28 | - | 100.00% |
| 2008-08-31 | - | 100.00% |
| 2008-05-31 | - | 100.00% |
| 2008-02-29 | - | 100.00% |
| 2007-08-31 | - | 100.00% |
| 2007-05-31 | - | 100.00% |
| 2007-02-28 | - | 100.00% |
| 2006-11-30 | - | 100.00% |
| 2006-05-31 | - | - |
Aytu BioPharma generated $17.99M in revenue during Q3 2024, up -21.54% compared to the previous quarter, and up 68.47% compared to the same period a year ago.
Aytu BioPharma Revenue Breakdown
Aytu BioPharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Jun 22 | Jun 21 | Jun 20 |
|---|---|---|---|
| Pediatric Portfolio | $16.08M | $24.43M | - |
| Consumer Health Portfolio | $35.55M | $32.95M | - |
| Primary Care And Devices Legacy | - | $8.25M | - |
| License Revenue | - | - | - |
| Product Revenue | - | - | $27.63M |
Aytu BioPharma's latest annual revenue breakdown by segment (product or service), as of Jun 22: Consumer Health Portfolio (68.85%), and Pediatric Portfolio (31.15%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | Dec 20 | Jun 20 | Mar 20 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Health | $3.97M | $8.93M | $8.25M | - | - | - | - | - | - | - | - | - | - |
| Consumer Health Portfolio | - | - | - | $9.00M | $8.71M | $10.34M | $8.48M | $8.01M | - | - | - | - | - |
| Pediatric Portfolio | - | - | - | $6.56M | $-25.41M | $13.59M | $14.45M | $13.46M | - | - | - | - | - |
| Discontinued Non-core Product | - | - | - | - | - | $1.70M | - | - | - | - | - | - | - |
| Primary Care Portfolio | - | - | - | - | - | $272.00K | $192.00K | - | - | - | - | - | - |
| Primary Care And Devices Legacy | - | - | - | - | - | - | - | $425.00K | - | - | - | - | - |
| Aytu Consumer Health | - | - | - | - | - | - | - | - | $8.36M | $7.93M | - | - | - |
| Aytu Bioscience | - | - | - | - | - | - | - | - | $5.13M | $7.21M | - | - | - |
| Product Revenue | - | - | - | - | - | - | - | - | - | - | $14.86M | $8.16M | - |
| License Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Aytu Womens Health | - | - | - | - | - | - | - | - | - | - | - | - | $46.00K |
| Aytu Bioscience Inc | - | - | - | - | - | - | - | - | - | - | - | - | $561.00K |
Aytu BioPharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Consumer Health (100.00%).
Aytu BioPharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Jun 22 | Jun 21 |
|---|---|---|
| Non-US | $2.06M | - |
| UNITED STATES | $94.61M | - |
| Pediatric Portfolio | $16.08M | - |
| Consumer Health Portfolio | $35.55M | - |
| Non Us | - | $4.95M |
| U | - | $60.69M |
Aytu BioPharma's latest annual revenue breakdown by geography, as of Jun 22: UNITED STATES (63.79%), Consumer Health Portfolio (23.97%), Pediatric Portfolio (10.85%), and Non-US (1.39%).
Quarterly Revenue by Country
| Country | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|
| Consumer Health | $8.93M | - | - | - | - | - |
| UNITED STATES | - | $27.48M | $27.20M | - | - | - |
| Non-US | - | $179.00K | $250.00K | - | - | - |
| U.S. | - | - | - | $23.75M | $22.55M | - |
| Non Us | - | - | - | - | - | $791.00K |
| U | - | - | - | - | - | $21.11M |
Aytu BioPharma's latest quarterly revenue breakdown by geography, as of Mar 23: Consumer Health (100.00%).
Aytu BioPharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| ESPR | Esperion Therapeutics | $116.33M | $73.83M |
| AYTU | Aytu BioPharma | $107.40M | $17.99M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| DERM | Journey Medical | $79.18M | $14.86M |
| FLGC | Flora Growth | $76.07M | $15.68M |
| NEPT | Neptune Wellness Solutions | $71.11M | $7.60M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| SBFM | Sunshine Biopharma | $39.85M | $9.30M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
| SNOA | Sonoma Pharmaceuticals | $12.73M | $3.44M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| JUPW | Safety Shot | $6.20M | $910.01K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| SXTC | China SXT Pharmaceuticals | $1.97M | $939.58K |
| ACRX | Talphera | $651.00K | $117.00K |
| SHPH | Shuttle Pharmaceuticals | - | - |
AYTU Revenue FAQ
What is Aytu BioPharma’s yearly revenue?
Aytu BioPharma's yearly revenue for 2023 was $107.4M, representing an increase of 11.10% compared to 2022. The company's yearly revenue for 2022 was $96.67M, representing an increase of 47.29% compared to 2021. AYTU's yearly revenue for 2021 was $65.63M, representing an increase of 137.52% compared to 2020.
What is Aytu BioPharma’s quarterly revenue?
Aytu BioPharma's quarterly revenue for Q3 2024 was $17.99M, a -21.54% decrease from the previous quarter (Q2 2024), and a -20.85% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $22.93M, a 3.78% increase from the previous quarter (Q1 2024), and a -12.73% decrease year-over-year (Q2 2023). AYTU's quarterly revenue for Q1 2024 was $22.1M, a -28.09% decrease from the previous quarter (Q4 2023), and a -20.09% decrease year-over-year (Q1 2023).
What is Aytu BioPharma’s revenue growth rate?
Aytu BioPharma's revenue growth rate for the last 3 years (2021-2023) was 63.64%, and for the last 5 years (2019-2023) was 1367.13%.
What are Aytu BioPharma’s revenue streams?
Aytu BioPharma's revenue streams in n 22 are Pediatric Portfolio, and Consumer Health Portfolio. Pediatric Portfolio generated $16.08M in revenue, accounting 31.15% of the company's total revenue, down -34.16% year-over-year. Consumer Health Portfolio generated $35.55M in revenue, accounting 68.85% of the company's total revenue, up 7.87% year-over-year.
What is Aytu BioPharma’s main source of revenue?
For the fiscal year ending Jun 22, the largest source of revenue of Aytu BioPharma was Consumer Health Portfolio. This segment made a revenue of $35.55M, representing 68.85% of the company's total revenue.